

REMARKS


The claims have been amended to eliminate multiple claim dependencies and to conform to U.S. practice. The changes to the claims are editorial and do not constitute new matter. Entry of the amendment is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 999710000008. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: July 20, 2001

By:



Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE

3. (Amended) The method of claim 1 [or claim 2], wherein IFN- β and cpn10 are administered together.

4. (Amended) The method of claim 1 [or claim 2], wherein IFN- β and cpn10 are administered separately

7. (Amended) The method of claim 4 [or claim 6], wherein IFN- β is administered by injection.

8. (Amended) The process of claim 1 [or claim 2], wherein the pharmaceutically effective amount of cpn10 and IFN- β comprises 5-60 mg of cpn10..

10. (Amended) The method of claim 1 [or claim 2], wherein the pharmaceutically-effective amount of cpn10 and IFN- β comprises 1-10 Million International Units (MIU) of IFN- β ..

20. (Amended) The kit of claim 17 [or claim 18], wherein said cpn10 is in tablet or capsule form.